Stifel has initiated coverage of Cytokinetics (CYTK) with a buy rating, citing its drug aficamten, valuation and upcoming ...

Stifel raised the firm’s price target on New Fortress Energy (NFE) to $23 from $17 and keeps a Buy rating on the shares. The firm notes that on ...

Stifel Nicolaus analyst Brad Reback maintained a Buy rating on Workiva (WK – Research Report) today and set a price target of $130.00. The ...

CEO Ron Kruszewski and Yahoo Finance Executive Editor Brian Sozzi at the 2025 World Economic Forum in Davos, Switzerland, to talk about the macro issues impacting the investment banking firm, ...

Thursday, January 23, 2025, marks the release of a new report by Stifel analysts on the US transport sector. The report outlines a cautious perspective on the industry's future, noting that while 2024 ...

Stifel analyst Brian Brophy raised the firm’s price target on Quanta Services (PWR) to $388 from $374 and keeps a Buy rating ...

Stifel Financial Corp. (NYSE: SF) will release its fourth quarter and full year 2024 financial results before the market ...

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

Fintel reports that on January 22, 2025, Stifel initiated coverage of Cytokinetics (NasdaqGS:CYTK) with a Buy recommendation.

Canadian investment dealer Eight Capital Corp. is winding down and many of its top staff are headed to Stifel Financial Corp.

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

On Wednesday, Vince Holding Corp (VNCE) stock saw a decline, ending the day at $2.35 which represents a decrease of $-0.60 or -20.34% from the prior close of $2.95. The stock opened at $2.95 and ...